A 42-year-old man developed cutaneous toxicity during treatment with erlotinib [time to reaction onset not stated]. He was diagnosed with lung lepidic predominant adenocarcinoma in December 2012. An allele-specific PCR and sequence analysis showed EGFR exon 20 mutation. His prior treatment consisted of carboplatin and pemetrexed, which resulted in stable disease. However, his disease progressed in September 2014, and he started receiving treatment with erlotinib [route and dosage not stated]. Subsequently, he developed minimal cutaneous toxicity [outcome not stated].

Author comment: "The patient tolerates [erlotinib treatment] with minimal cutaneous toxicity and has stable disease 10 months after initiation of targeted treatment."